Molecular mechanisms and clinical management of cancer bone metastasis

Abstract

As one of the most common metastatic sites of malignancies, bone has a unique microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated capillaries in the bone, bone matrix, and bone cells, including osteoblasts and osteoclasts, together maintain the homeostasis of the bone microenvironment. In contrast, tumor-derived factors act on bone components, leading to subsequent bone resorption or excessive bone formation. The various pathways involved also provide multiple targets for therapeutic strategies against bone metastases. In this review, we summarize the current understanding of the mechanism of bone metastases. Based on the general process of bone metastases, we specifically highlight the complex crosstalk between tumor cells and the bone microenvironment and the current management of cancer bone metastases.

References

[1] Ruoslahti E. How cancer spreads. Sci. Am., 1996, 275:72-77

[2] Rusciano D, Burger MM. Why do cancer cells metastasize into particular organs? Bioessays, 1992, 14:185-194

[3] Coleman RE. Skeletal complications of malignancy. Cancer, 1997, 80:1588-1594

[4] Kraljevic Pavelic S, Sedic M, Bosnjak H, Spaventi S, Pavelic K. Metastasis: new perspectives on an old problem. Mol. Cancer, 2011, 10

[5] Guise TA. The vicious cycle of bone metastases. J. Musculoskelet. Neuronal Interact., 2002, 2:570-572

[6] Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer, 2009, 9:274-284

[7] Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med, 2004, 350:1655-1664

[8] Gupta GP, Massague J. Cancer metastasis: building a framework. Cell, 2006, 127:679-695

[9] Saki N, Abroun S, Farshdousti Hagh M, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J., 2011, 13:131-136

[10] Chiang AC, Massague J. Molecular basis of metastasis. N. Engl. J. Med, 2008, 359:2814-2823

[11] Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control, 2012, 19:92-101

[12] Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev., 1989, 8:98-101

[13] Kaplan RN et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 2005, 438:820-827

[14] Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer, 2003, 3:453-458

[15] Langley RR, Fidler IJ. The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer, 2011, 128:2527-2535

[16] Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci., 2012, 103:626-631

[17] Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol., 2011, 21:139-146

[18] Peinado H et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer, 2017, 17:302-317

[19] Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat. Rev. Immunol., 2015, 15:73-86

[20] Kawai H et al. Characterization and potential roles of bone marrow-derived stromal cells in cancer development and metastasis. Int. J. Med. Sci., 2018, 15:1406-1414

[21] Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev., 2006, 25:521-529

[22] Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer, 2009, 9:285-293

[23] Sahoo M et al. Hematopoietic stem cell specific V-ATPase controls breast cancer progression and metastasis via cytotoxic T cells. Oncotarget, 2018, 9:33215-33231

[24] Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res., 2006, 66:11089-11093

[25] Atkins GJ, Findlay DM. Osteocyte regulation of bone mineral: a little give and take. Osteoporos. Int., 2012, 23:2067-2079

[26] Bonewald LF. The amazing osteocyte. J. Bone Miner. Res., 2011, 26:229-238

[27] Winkler DG et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J., 2003, 22:6267-6276

[28] Nakashima T et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med., 2011, 17:1231-1234

[29] Xiong J et al. Matrix-embedded cells control osteoclast formation. Nat. Med., 2011, 17:1235-1241

[30] Feng JQ et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet., 2006, 38:1310-1315

[31] Kramer I et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol., 2010, 30:3071-3085

[32] Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann. N. Y. Acad. Sci., 2007, 1116:281-290

[33] Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol., 2012, 8:276-286

[34] Lin H, Sohn J, Shen H, Langhans MT, Tuan RS. Bone marrow mesenchymal stem cells: aging and tissue engineering applications to enhance bone healing. Biomaterials, 2019, 203:96-110

[35] Pittenger MF et al. Multilineage potential of adult human mesenchymal stem cells. Science, 1999, 284:143-147

[36] Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve, 1995, 18:1417-1426

[37] Reyes M et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood, 2001, 98:2615-2625

[38] Gao F et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis., 2016, 7

[39] Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2005, 105:1815-1822

[40] Dejbakhsh-Jones S, Jerabek L, Weissman IL, Strober S. Extrathymic maturation of alpha beta T cells from hemopoietic stem cells. J. Immunol., 1995, 155:3338-3344

[41] Barda-Saad M, Rozenszajn LA, Globerson A, Zhang AS, Zipori D. Selective adhesion of immature thymocytes to bone marrow stromal cells: relevance to T cell lymphopoiesis. Exp. Hematol., 1996, 24:386-391

[42] Di Nicola M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 2002, 99:3838-3843

[43] Krampera M et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 2006, 24:386-398

[44] Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta, 2012, 1820:940-948

[45] Hoshino A et al. Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527:329-335

[46] Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat. Rev. Cancer, 2015, 15:96-109

[47] Zimmer DB, Eubanks JO, Ramakrishnan D, Criscitiello MF. Evolution of the S100 family of calcium sensor proteins. Cell Calcium, 2013, 53:170-179

[48] Moon A et al. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol. Cancer Res., 2008, 6:1544-1553

[49] Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am. J. Respir. Cell Mol. Biol., 1991, 5:206-210

[50] Levental KR et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell, 2009, 139:891-906

[51] Reynaud C et al. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res., 2017, 77:268-278

[52] Cox TR et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature, 2015, 522:106-110

[53] Monteiro AC et al. T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS ONE, 2013, 8

[54] Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer, 2012, 12:540-552

[55] Cox TR, Gartland A, Erler JT. Lysyl Oxidase, a targetable secreted molecule involved in cancer metastasis. Cancer Res., 2016, 76:188-192

[56] Sun W et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov., 2016, 2:16015

[57] Deng L et al. Osteoblast-derived microvesicles: a novel mechanism for communication between osteoblasts and osteoclasts. Bone, 2015, 79:37-42

[58] Zhang HC et al. Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev., 2012, 21:3289-3297

[59] Huynh N et al. Characterization of regulatory extracellular vesicles from osteoclasts. J. Dent. Res., 2016, 95:673-679

[60] Yuan FL et al. Osteoclast-derived extracellular vesicles: novel regulators of osteoclastogenesis and osteoclast-osteoblasts communication in bone remodeling. Front. Physiol., 2018, 9:628

[61] Li D et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun., 2016, 7

[62] Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2:38-47

[63] Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev., 2004, 23:293-310

[64] Arnett T. Regulation of bone cell function by acid-base balance. Proc. Nutr. Soc., 2003, 62:511-520

[65] Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res., 2006, 66:5216-5223

[66] Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J. Clin. Oncol., 2004, 22:2942-2953

[67] Taichman RS et al. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE, 2013, 8

[68] Roato I. Bone metastases: when and how lung cancer interacts with bone. World J. Clin. Oncol., 2014, 5:149-155

[69] Lu X et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell, 2011, 20:701-714

[70] Muto A et al. Lineage-committed osteoclast precursors circulate in blood and settle down into bone. J. Bone Miner. Res., 2011, 26:2978-2990

[71] Lee AW, States DJ. Both src-dependent and -independent mechanisms mediate phosphatidylinositol 3-kinase regulation of colony-stimulating factor 1-activated mitogen-activated protein kinases in myeloid progenitors. Mol. Cell. Biol., 2000, 20:6779-6798

[72] Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin. Cancer Res., 2012, 18:326-335

[73] Dougall WC, Holen I, Gonzalez Suarez E. Targeting RANKL in metastasis. Bonekey Rep., 2014, 3:519

[74] Anderson DM et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997, 390:175-179

[75] Li J et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl Acad. Sci. USA, 2000, 97:1566-1571

[76] Santini D et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE, 2011, 6

[77] Jones DH et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 2006, 440:692-696

[78] Suda T et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 1999, 20:345-357

[79] Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun., 1999, 256:449-455

[80] Maeda K et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med., 2012, 18:405-412

[81] Karst M, Gorny G, Galvin RJ, Oursler MJ. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J. Cell. Physiol., 2004, 200:99-106

[82] Hodge JM, Collier FM, Pavlos NJ, Kirkland MA, Nicholson GC. M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS ONE, 2011, 6

[83] Naito A et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells, 1999, 4:353-362

[84] Armstrong AP et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J. Biol. Chem., 2002, 277:44347-44356

[85] Hu R et al. Eos, MITF, and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid progenitors. Mol. Cell. Biol., 2007, 27:4018-4027

[86] Taguchi Y, Gohda J, Koga T, Takayanagi H, Inoue J. A unique domain in RANK is required for Gab2 and PLCgamma2 binding to establish osteoclastogenic signals. Genes Cells, 2009, 14:1331-1345

[87] Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev., 2009, 231:241-256

[88] Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Investig., 2006, 116:2869-2879

[89] Lee SH et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat. Med., 2006, 12:1403-1409

[90] Kukita T et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med., 2004, 200:941-946

[91] Yagi M et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med., 2005, 202:345-351

[92] Campbell JP et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol., 2012, 10

[93] Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer, 2003, 97:834-839

[94] Park HR et al. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J. Korean Med. Sci., 2003, 18:541-546

[95] Thomas RJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 1999, 140:4451-4458

[96] Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2002, 2:584-593

[97] Powell GJ et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res., 1991, 51:3059-3061

[98] Vargas SJ et al. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J. Bone Miner. Res., 1992, 7:971-979

[99] Kohno N et al. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg. Today, 1994, 24:215-220

[100] Guise TA et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Investig., 1996, 98:1544-1549

[101] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423:337-342

[102] Lacey DL et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov., 2012, 11:401-419

[103] Yasuda H et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 1998, 139:1329-1337

[104] Roodman GD. Biology of osteoclast activation in cancer. J. Clin. Oncol., 2001, 19:3562-3571

[105] Irie A et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone, 2007, 41:165-174

[106] Lamoureux F et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res., 2009, 69:526-536

[107] Corey E et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res., 2005, 65:1710-1718

[108] Nyambo R et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J. Bone Miner. Res., 2004, 19:1712-1721

[109] Holen I, Croucher PI, Hamdy FC, Eaton CL, Osteoprotegerin OPG. is a survival factor for human prostate cancer cells. Cancer Res., 2002, 62:1619-1623

[110] Brown JM et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology, 2001, 57:611-616

[111] Tae CH et al. Significance of calcium-sensing receptor expression in gastric cancer. Scand. J. Gastroenterol., 2016, 51:67-72

[112] Singh N, Aslam MN, Varani J, Chakrabarty S. Induction of calcium sensing receptor in human colon cancer cells by calcium, vitamin D and aquamin: promotion of a more differentiated, less malignant and indolent phenotype. Mol. Carcinog., 2015, 54:543-553

[113] Diez-Fraile A, Lammens T, Benoit Y, D’Herde KG. The calcium-sensing receptor as a regulator of cellular fate in normal and pathological conditions. Curr. Mol. Med., 2013, 13:282-295

[114] Joeckel E et al. High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor. Mol. Cancer, 2014, 13

[115] Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int. J. Oncol., 2001, 19:379-382

[116] Frees S et al. Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget, 2018, 9:15766-15779

[117] Boudot C et al. Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. Oncotarget, 2017, 8:56460-56472

[118] Wu Y, Zhou BP. TNF-alpha/NF-kappaB/snail pathway in cancer cell migration and invasion. Br. J. Cancer, 2010, 102:639-644

[119] Ji H et al. TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat. Commun., 2014, 5

[120] Calcinotto A et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J. Immunol., 2012, 188:2687-2694

[121] Ikemoto S et al. TNF alpha, IL-1 beta and IL-6 production by peripheral blood monocytes in patients with renal cell carcinoma. Anticancer Res., 2000, 20:317-321

[122] Balkwill F, Joffroy C. TNF: a tumor-suppressing factor or a tumor-promoting factor? Future Oncol., 2010, 6:1833-1836

[123] Walsh MC et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol., 2006, 24:33-63

[124] Kitaura H et al. Immunological reaction in TNF-alpha-mediated osteoclast formation and bone resorption in vitro and in vivo. Clin. Dev. Immunol., 2013, 2013:181849

[125] Kitaura H et al. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Investig., 2005, 115:3418-3427

[126] Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood, 2000, 96:1873-1878

[127] Komine M et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone, 2001, 28:474-483

[128] Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem., 2000, 275:4858-4864

[129] Kanazawa K, Azuma Y, Nakano H, Kudo A. TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis. J. Bone Miner. Res., 2003, 18:443-450

[130] Kanazawa K, Kudo A. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. J. Bone Miner. Res., 2005, 20:840-847

[131] Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem., 2001, 276:563-568

[132] Yao Z et al. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors. J. Biol. Chem., 2017, 292:10169-10179

[133] Hwang SJ et al. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther., 2012, 14:R14

[134] Corrado A, Neve A, Maruotti N, Cantatore FP. Bone effects of biologic drugs in rheumatoid arthritis. Clin. Dev. Immunol., 2013, 2013:945945

[135] Tani-Ishii N, Tsunoda A, Teranaka T, Umemoto T. Autocrine regulation of osteoclast formation and bone resorption by IL-1 alpha and TNF alpha. J. Dent. Res., 1999, 78:1617-1623

[136] Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. Estrogen’s bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J. Clin. Investig., 1999, 103:1409-1418

[137] Kim JH et al. The mechanism of osteoclast differentiation induced by IL-1. J. Immunol., 2009, 183:1862-1870

[138] Jules J et al. Molecular basis of requirement of receptor activator of nuclear factor kappaB signaling for interleukin 1-mediated osteoclastogenesis. J. Biol. Chem., 2012, 287:15728-15738

[139] Ruscitti P et al. The role of IL-1beta in the bone loss during rheumatic diseases. Mediators Inflamm., 2015, 2015:782382

[140] Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Investig., 2005, 115:282-290

[141] Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov., 2012, 11:633-652

[142] Rose-John, S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10, a028415 (2018).

[143] Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J. Biol. Chem., 2008, 283:11535-11540

[144] Kudo O et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone, 2003, 32:1-7

[145] Wakabayashi H et al. Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line. Breast Cancer, 2018, 25:566-574

[146] Amarasekara DS et al. Regulation of osteoclast differentiation by cytokine networks. Immune Netw., 2018, 18

[147] Feng W et al. Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-kappaB, ERK and JNK signaling pathways. Sci. Rep., 2017, 7

[148] Heinrich PC et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J., 2003, 374:1-20

[149] Argast GM et al. Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs, 2011, 193:114-132

[150] Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL. Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2. Clin. Exp. Metastasis, 2004, 21:167-176

[151] Jorcyk CL, Holzer RG, Ryan RE. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine, 2006, 33:323-336

[152] Hui W, Rowan AD, Richards CD, Cawston TE. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum., 2003, 48:3404-3418

[153] Bolin C et al. Oncostatin M promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer, 2012, 3:117-130

[154] Aguila HL et al. Osteoblast-specific overexpression of human interleukin-7 rescues the bone mass phenotype of interleukin-7-deficient female mice. J. Bone Miner. Res., 2012, 27:1030-1042

[155] Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl Acad. Sci. USA, 2003, 100:125-130

[156] Yu J et al. Generation of an osteoblast-based artificial niche that supports in vitro B lymphopoiesis. Exp. Mol. Med., 2017, 49

[157] Roato I et al. IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS ONE, 2006, 1

[158] Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J. Immunol., 2003, 170:2655-2662

[159] Kim JH et al. Interleukin-7 induces osteoclast formation via STAT5, independent of receptor activator of NF-kappaB ligand. Front. Immunol., 2017, 8:1376

[160] Roy LD et al. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer, 2014, 14

[161] Balani D, Aeberli D, Hofstetter W, Seitz M. Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. Arthritis Rheum., 2013, 65:436-446

[162] Shi Y et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Res., 2006, 16:126-133

[163] Lee MS et al. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway. J. Immunol., 2009, 183:3390-3399

[164] Ruef N et al. Granulocyte-macrophage colony-stimulating factor-dependent CD11c-positive cells differentiate into active osteoclasts. Bone, 2017, 97:267-277

[165] Atanga E, Dolder S, Dauwalder T, Wetterwald A, Hofstetter W. TNFalpha inhibits the development of osteoclasts through osteoblast-derived GM-CSF. Bone, 2011, 49:1090-1100

[166] Paul SR et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. Natl Acad. Sci. USA, 1990, 87:7512-7516

[167] Zhang Y et al. Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Oncogene, 1998, 16:693-703

[168] Romas E et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med., 1996, 183:2581-2591

[169] Elias JA, Tang W, Horowitz MC. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology, 1995, 136:489-498

[170] Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J. Clin. Investig., 1994, 93:1516-1524

[171] Ren L, Wang X, Dong Z, Liu J, Zhang S. Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway. Med. Oncol., 2013, 30:634

[172] Bendre MS et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone, 2003, 33:28-37

[173] Bendre MS et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res., 2005, 65:11001-11009

[174] Kopesky P et al. Autocrine signaling is a key regulatory element during osteoclastogenesis. Biol. Open, 2014, 3:767-776

[175] Liu Y et al. Role of IL-8 and its receptor in anti-citrullinated protein antibody mediated osteoclastogenesis in RA. Ann. Rheum. Dis., 2016, 75:AB0078

[176] Bhattacharyya RS, Stern PH. IGF-I and MAP kinase involvement in the stimulatory effects of LNCaP prostate cancer cell conditioned media on cell proliferation and protein synthesis in MC3T3-E1 osteoblastic cells. J. Cell. Biochem., 2003, 90:925-937

[177] Feeley BT et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J. Bone Miner. Res., 2005, 20:2189-2199

[178] Kitagawa Y et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res., 2005, 65:10921-10929

[179] Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer, 2003, 97:779-784

[180] Smollich M, Wulfing P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr. Vasc. Pharm., 2007, 5:239-248

[181] Yin JJ et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl Acad. Sci. USA, 2003, 100:10954-10959

[182] Clines GA et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol. Endocrinol., 2007, 21:486-498

[183] Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol., 2010, 37:S2-S14

[184] Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res., 2005, 65:7554-7560

[185] Carducci MA et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J. Clin. Oncol., 2003, 21:679-689

[186] Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia, 2005, 7:631-637

[187] Van Sant C et al. Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway. Mol. Cancer Ther., 2007, 6:253-261

[188] Bendinelli P et al. Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer. Biochim. Biophys. Acta, 2014, 1843:815-826

[189] Maroni P et al. High SPARC expression starting from dysplasia, associated with breast carcinoma, is predictive for bone metastasis without enhancement of plasma levels. Int. J. Mol. Sci., 2015, 16:28108-28122

[190] Zhong X, Wang H, Huang S. Endothelin-1 induces interleukin-18 expression in human osteoblasts. Arch. Oral. Biol., 2014, 59:289-296

[191] Matteucci, E. et al. Microenvironment stimuli HGF and hypoxia differently affected miR-125b and Ets-1 function with opposite effects on the invasiveness of bone metastatic cells: a comparison with breast carcinoma cells. Int. J. Mol. Sci. 19, 258 (2018).

[192] Hall CL, Keller ET. The role of Wnts in bone metastases. Cancer Metastasis Rev., 2006, 25:551-558

[193] Zhuang X et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat. Cell Biol., 2017, 19:1274-1285

[194] Kasoha M et al. Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases. Clin. Exp. Metastasis, 2018, 35:763-775

[195] Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet., 2001, 10:537-543

[196] Brunkow ME et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet., 2001, 68:577-589

[197] Li X et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem., 2005, 280:19883-19887

[198] Glinka A et al. LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and Wnt/PCP signalling. EMBO Rep., 2011, 12:1055-1061

[199] ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Joint Surg. Am., 2008, 90:31-35

[200] Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev. Mol. Med., 2008, 10

[201] Liao J, McCauley LK. Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev., 2006, 25:559-571

[202] Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem. Biophys. Res. Commun., 2005, 327:468-472

[203] Hoey RP et al. The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br. J. Cancer, 2003, 88:567-573

[204] Shen X, Falzon M. PTH-related protein enhances LoVo colon cancer cell proliferation, adhesion, and integrin expression. Regul. Pept., 2005, 125:17-27

[205] Massfelder T et al. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res., 2004, 64:180-188

[206] Ma YL et al. Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 2001, 142:4047-4405

[207] Liao J et al. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int. J. Cancer, 2008, 123:2267-2278

[208] LeBeau AM, Kostova M, Craik CS, Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biol. Chem., 2010, 391:333-343

[209] Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol., 1996, 156:526-531

[210] Schluter KD, Katzer C, Piper HM. A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br. J. Pharmacol., 2001, 132:427-432

[211] Fielder PJ et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul., 1994, 4:164-172

[212] Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun., 1993, 192:940-947

[213] Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate, 2007, 67:312-329

[214] Lee YC et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res., 2011, 71:5194-5203

[215] Li ZG et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Investig., 2008, 118:2697-2710

[216] Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer, 2002, 2:563-572

[217] Johnson RW, Suva LJ. Hallmarks of bone metastasis. Calcif. Tissue Int., 2018, 102:141-151

[218] Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2:161-174

[219] Djonov V et al. Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int. J. Oncol., 2002, 21:25-30

[220] Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin. Cancer Res., 2004, 10:3110-3116

[221] Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res., 2001, 21:3821-3828

[222] Upadhyay J et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin. Cancer Res., 1999, 5:4105-4110

[223] Nakopoulou L et al. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res. Treat., 2003, 77:145-155

[224] Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int. J. Cancer, 2003, 106:745-751

[225] Benelli R et al. Inhibition of AIDS-Kaposi’s sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol. Res., 1994, 6:251-257

[226] Anand-Apte B et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Investig. Ophthalmol. Vis. Sci., 1997, 38:817-823

[227] Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell, 1998, 95:365-377

[228] Vu TH et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 1998, 93:411-422

[229] Itoh T et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 1998, 58:1048-1051

[230] Schnaper HW et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell. Physiol., 1993, 156:235-246

[231] Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med. Sci. Monit., 2009, 15:RA32-40

[232] Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer, 2003, 89:1270-1275

[233] Chen Y, Wang X, Chen G, Dong C, Zhang D. The impact of matrix metalloproteinase 2 on prognosis and clinicopathology of breast cancer patients: a systematic meta-analysis. PLoS ONE, 2015, 10

[234] Hashimoto G et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem., 2002, 277:36288-36295

[235] Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int. J. Cancer, 2010, 127:1081-1095

[236] Heroult M et al. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene, 2004, 23:1745-1753

[237] O’Reilly MS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88:277-285

[238] Ramchandran R et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem. Biophys. Res. Commun., 1999, 255:735-739

[239] Colorado PC et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res., 2000, 60:2520-2526

[240] Tauro, M. & Lynch, C. C. Cutting to the chase: how matrix metalloproteinase-2 activity controls breast-cancer-to-bone metastasis. Cancers 10, 185 (2018).

[241] Chen PC et al. Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression. J. Hematol. Oncol., 2017, 10:33

[242] Lynch CC et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell, 2005, 7:485-496

[243] Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol. Cancer Res., 2010, 8:459-470

[244] Wang C et al. BMP-6 inhibits MMP-9 expression by regulating heme oxygenase-1 in MCF-7 breast cancer cells. J. Cancer Res. Clin. Oncol., 2011, 137:985-995

[245] Freije JM et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem., 1994, 269:16766-16773

[246] Mauviel A. Cytokine regulation of metalloproteinase gene expression. J. Cell. Biochem., 1993, 53:288-295

[247] Johansson N et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am. J. Pathol., 1997, 151:499-508

[248] Cazorla M et al. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J. Pathol., 1998, 186:144-150

[249] Ren X-F, Mu L-P, Jiang Y-S, Wang L, Ma J-F. LY2109761 inhibits metastasis and enhances chemosensitivity in osteosarcoma MG-63 cells. Eur. Rev. Med. Pharmacol., 2015, 19 7 1182-1190

[250] Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev., 2006, 25:573-587

[251] Sun X et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev., 2010, 29:709-722

[252] Muller A et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410:50-56

[253] Kojima Y et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl Acad. Sci. USA, 2010, 107:20009-20014

[254] Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer, 2004, 4:540-550

[255] Hattermann K et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res., 2010, 70:3299-3308

[256] Miao Z et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl Acad. Sci. USA, 2007, 104:15735-15740

[257] Orimo A et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 2005, 121:335-348

[258] Kishimoto H et al. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. Carcinogenesis, 2005, 26:1706-1715

[259] Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 2006, 107:1761-1767

[260] Sun YX et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res., 2005, 20:318-329

[261] Taichman RS et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res., 2002, 62:1832-1837

[262] Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer, 2010, 103:1671-1679

[263] Maderna E, Salmaggi A, Calatozzolo C, Limido L, Pollo B. Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol. Ther., 2007, 6:1018-1024

[264] Xu L et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res., 2009, 69:7905-7910

[265] Engl T et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia, 2006, 8:290-301

[266] Havens AM et al. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer, 2006, 6

[267] Cabioglu N et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res., 2005, 65:6493-6497

[268] Kang Y et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3:537-549

[269] Liang Z et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res., 2005, 65:967-971

[270] Richert MM et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep., 2009, 21:761-767

[271] Chinni SR et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate, 2006, 66:32-48

[272] Wang J et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal., 2005, 17:1578-1592

[273] Glinskii OV et al. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia, 2005, 7:522-527

[274] Glinsky VV et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res., 2001, 61:4851-4857

[275] Hill A, McFarlane S, Johnston PG, Waugh DJ. The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett., 2006, 237:1-9

[276] Pinilla S et al. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett., 2009, 284:80-85

[277] Karnoub AE et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 2007, 449:557-563

[278] Urata S et al. C-C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. Cancer Sci., 2018, 109:724-731

[279] Kim M et al. The lymphotactin receptor is expressed in epithelial ovarian carcinoma and contributes to cell migration and proliferation. Mol. Cancer Res., 2012, 10:1419-1429

[280] Khurram SA et al. Functional expression of the chemokine receptor XCR1 on oral epithelial cells. J. Pathol., 2010, 221:153-163

[281] Gantsev SK et al. The role of inflammatory chemokines in lymphoid neoorganogenesis in breast cancer. Biomed. Pharmacother., 2013, 67:363-366

[282] Sun YX et al. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate, 2007, 67:61-73

[283] Valcarcel M et al. Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2. J. Transl. Med., 2011, 9

[284] Denkert C et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res., 2001, 61:303-308

[285] Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat. Rev. Cancer, 2011, 11:411-425

[286] Mohammad KS et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE, 2009, 4

[287] Korpal M et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med., 2009, 15:960-966

[288] Kang Y et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl Acad. Sci. USA, 2005, 102:13909-13914

[289] Juarez P, Guise TA. TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone, 2011, 48:23-29

[290] Serganova I et al. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J., 2009, 23:2662-2672

[291] Baselga J et al. TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers, 2008, 13:217-236

[292] Buijs JT et al. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin. Exp. Metastasis, 2007, 24:609-617

[293] Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer, 2013, 13:788-799

[294] Yin JJ et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Investig., 1999, 103:197-206

[295] Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell, 2011, 19:192-205

[296] Wan X et al. Effect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growth. Bone, 2012, 50:695-703

[297] Kawai M, Rosen CJ. The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol. Metab. Clin. North Am., 2012, 41:323-333

[298] Hiraga T et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res., 2012, 72:4238-4249

[299] Zhang XH et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell, 2013, 154:1060-1073

[300] Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin. Investig. Drugs, 2001, 10:1099-1115

[301] Koutsilieris M et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J. Clin. Endocrinol. Metab., 2001, 86:5729-5736

[302] Koutsilieris M et al. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin. Investig. Drugs, 2002, 11:283-293

[303] Koutsilieris M et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin. Cancer Res., 2004, 10:4398-4405

[304] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136:215-233

[305] Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat. Cell Biol., 2010, 12:209-211

[306] Ma L et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol., 2010, 12:247-256

[307] Ren D et al. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR145. Int. J. Oncol., 2013, 42:1473-1481

[308] Ren D et al. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kappaB signaling pathway. Mol. Cancer, 2017, 16

[309] Colden M et al. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis., 2017, 8

[310] Siu MK et al. Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene, 2015, 34:4767-4776

[311] Lou G et al. Direct targeting sperm-associated antigen 9 by miR-141 influences hepatocellular carcinoma cell growth and metastasis via JNK pathway. J. Exp. Clin. Cancer Res. : C, 2016, 35:14

[312] Liu C et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat. Commun., 2017, 8

[313] Huang S et al. Downregulation of miR-141-3p promotes bone metastasis via activating NF-kappaB signaling in prostate cancer. J. Exp. Clin. Cancer Res., 2017, 36:173

[314] Ren D et al. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Cell Tissue Res., 2014, 358:763-778

[315] Guo W et al. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J. Cell. Biochem., 2013, 114:1606-1615

[316] Huang S et al. Transcriptional downregulation of miR-133b by REST promotes prostate cancer metastasis to bone via activating TGF-beta signaling. Cell Death Dis., 2018, 9:779

[317] Wa Q et al. Downregulation of miR19a3p promotes invasion, migration and bone metastasis via activating TGFbeta signaling in prostate cancer. Oncol. Rep., 2018, 39:81-90

[318] Croset M, Kan C, Clezardin P. Tumour-derived miRNAs and bone metastasis. Bonekey Rep., 2015, 4:688

[319] Taipaleenmaki H et al. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease. Cancer Res., 2015, 75:1433-1444

[320] Croset M et al. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J. Bone Miner. Res., 2014, 29:1886-1899

[321] David M et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE, 2010, 5

[322] Leblanc R et al. Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood, 2014, 124:3141-3150

[323] D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J. Bone Oncol., 2019, 15:004-4

[324] Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).

[325] Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 319, 1681–1692 (1988).

[326] Pyrhonen S et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat., 1999, 56:133-143

[327] Fisher B et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 1998, 90:1371-1388

[328] Cauley JA et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat., 2001, 65:125-134

[329] Howell A et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 2005, 365:60-62

[330] Coates AS et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol., 2007, 25:486-492

[331] Coombes RC et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 2007, 369:559-570

[332] Arimidex,Tamoxifen, Alone or in Combination (ATAC) Trialists' Group et al Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol., 2008, 9:45-53

[333] Buzdar A et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol., 2001, 19:3357-3366

[334] Buzdar AU. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J. Clin. Oncol., 2004, 22:3199-3200

[335] Hong N et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: a propensity score-matched cohort study. Eur. J. Cancer, 2017, 82:103-114

[336] De Placido S et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol., 2018, 19:474-485

[337] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).

[338] Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med., 2004, 350:1081-1092

[339] Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 2005, 366:455-462

[340] Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol., 2005, 23:5138-5147

[341] Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst., 2005, 97:1262-1271

[342] Mamounas EP. Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. Oncology, 2001, 15:35-39

[343] Heshmati HM et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J. Bone Miner. Res., 2002, 17:172-178

[344] Bouvard B et al. Fracture incidence after 3 years of aromatase inhibitor therapy. Ann. Oncol., 2014, 25:843-847

[345] Heidenreich A et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol., 2014, 65:467-479

[346] Huggins C, Stevens RE Jr., Hodges CV. Studies on prostatic cancer: ii. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg., 1941, 43:209-223

[347] Lepor H, Shore ND. LHRH agonists for the treatment of prostate cancer: 2012. Rev. Urol., 2012, 14:1-12

[348] Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int., 2000, 86:449-452

[349] Smith MR et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med, 2001, 345:948-955

[350] Oefelein MG et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J. Urol., 2001, 166:1724-1728

[351] Melton LJ III et al. Fracture risk following bilateral orchiectomy. J. Urol., 2003, 169:1747-1750

[352] Fizazi K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 2012, 13:983-992

[353] Ryan CJ et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 2015, 16:152-160

[354] Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 2012, 367:1187-1197

[355] Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med., 2014, 371:1755-1756

[356] Sonpavde G et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin. Genitourin. Cancer, 2015, 13:309-318

[357] Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer, 2000, 88:2934-2939

[358] Quilty PM et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother. Oncol., 1994, 31:33-40

[359] Roque IFM, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. WITHDRAWN: radioisotopes for metastatic bone pain. Cochrane Database Syst. Rev., 2017, 3:CD003347

[360] Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol., 2014, 15:1397-1406

[361] Morris MJ et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J. Clin. Oncol., 2009, 27:2436-2442

[362] Tu SM et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet, 2001, 357:336-341

[363] Sciuto R et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J. Nucl. Med, 2002, 43:79-86

[364] Fizazi K et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol., 2009, 27:2429-2435

[365] Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J. Clin. Oncol., 2007, 25:1423-1436

[366] McQuay HJ, Carroll D, Moore RA. Radiotherapy for painful bone metastases: a systematic review. Clin. Oncol., 1997, 9:150-154

[367] Wu JS et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J. Radiat. Oncol. Biol. Phys., 2003, 55:594-605

[368] Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy–a systematic review of randomised trials. Clin. Oncol., 2003, 15:345-352

[369] Hartsell WF et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst., 2005, 97:798-804

[370] Higinbotham NL, Marcove RC. The management of pathological fractures. J. Trauma, 1965, 5:792-798

[371] Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., 2006, 12:6243s-6249s

[372] Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer, 2007, 109:2334-2342

[373] Forsberg JA, Eberhardt J, Boland PJ, Wedin R, Healey JH. Estimating survival in patients with operable skeletal metastases: an application of a bayesian belief network. PLoS ONE, 2011, 6

[374] Ratasvuori M et al. Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases. J. Surg. Oncol., 2014, 110:360-365

[375] Harvey N, Ahlmann ER, Allison DC, Wang L, Menendez LR. Endoprostheses last longer than intramedullary devices in proximal femur metastases. Clin. Orthop. Relat. Res., 2012, 470:684-691

[376] Harrington KD. Orthopedic surgical management of skeletal complications of malignancy. Cancer, 1997, 80:1614-1627

[377] Facchini G et al. Palliative embolization for metastases of the spine. Eur. J. Orthop. Surg. Traumatol., 2016, 26:247-252

[378] Rossi G et al. Embolisation of bone metastases from renal cancer. Radio. Med., 2013, 118:291-302

[379] Cheung FH. The practicing orthopedic surgeon's guide to managing long bone metastases. Orthop. Clin. North Am., 2014, 45:109-119

[380] Willeumier JJ, van der Linden YM, van de Sande MAJ, Dijkstra PDS. Treatment of pathological fractures of the long bones. EFORT Open Rev., 2016, 1:136-145

[381] Errani C et al. Treatment for long bone metastases based on a systematic literature review. Eur. J. Orthop. Surg. Traumatol., 2017, 27:205-211

[382] Sun G, Jin P, Liu XW, Li M, Li L. Cementoplasty for managing painful bone metastases outside the spine. Eur. Radio., 2014, 24:731-737

[383] Eisenberg E, Shay L, Keidar Z, Amit A, Militianu D. Magnetic resonance-guided focused ultrasound surgery for bone metastasis: from pain palliation to biological ablation? J. Pain. Symptom Manag., 2018, 56:158-162

[384] Hurwitz MD et al. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J. Natl Cancer Inst., 2014, 106:dju082

[385] Liberman B et al. Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann. Surg. Oncol., 2009, 16:140-146

[386] Gianfelice D et al. Palliative treatment of painful bone metastases with MR imaging–guided focused ultrasound. Radiology, 2008, 249:355-363

[387] Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res., 2006, 12:6222s-6230s

[388] Lehenkari PP et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharm., 2002, 61:1255-1262

[389] Pickup MW, Owens P, Moses HL. TGF-β, bone morphogenetic protein, and activin signaling and the tumor microenvironment. Cold Spring Harb Perspect Biol., 2017, 9 5 a022285

[390] Buijs JT, Stayrook KR, Guise TA. The role of TGF-β in bone metastasis: Novel therapeutic perspectives. Bonekey Rep., 2012, 1:96-705

[391] Dalle Carbonare L et al. Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. Mol. Cell. Endocrinol., 2005, 240:23-31

[392] Van Poznak C et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J. Clin. Pathol., 2006, 59:56-63

[393] Soltau J et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res., 2008, 28:933-941

[394] Backman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res., 2008, 28:1551-1557

[395] Ribatti D et al. Clodronate inhibits angiogenesis in vitro and in vivo. Oncol. Rep., 2008, 19:1109-1112

[396] Hashimoto K et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun., 2007, 354:478-484

[397] Tang X et al. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int. J. Cancer, 2010, 126:90-103

[398] Zhou JZ et al. Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis. Oncogene, 2016, 35:5597-5607

[399] Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol., 2001, 28:35-44

[400] Kokufu I, Kohno N, Yamamoto M, Takao S. Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes. Oncol. Lett., 2010, 1:247-252

[401] Lipton A et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer, 2000, 88:1082-1090

[402] Berenson JR et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001, 91:1191-1200

[403] Rosen LS et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J., 2001, 7:377-387

[404] Atula S et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf., 2003, 26:661-671

[405] Powles T et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res., 2006, 8:R13

[406] Dearnaley DP et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl Cancer Inst., 2003, 95:1300-1311

[407] Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst., 2002, 94:1458-1468

[408] Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol. Clin. North Am., 2004, 31:331-352

[409] Khosla S et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res., 2007, 22:1479-1491

[410] Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med., 2006, 144:753-761

[411] Rodriguez-Lozano FJ, Onate-Sanchez RE. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med. Oral Patol. Oral Cir. Bucal, 2016, 21:e595-e600

[412] Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int. J. Cancer, 2005, 113:364-371

[413] Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev., 2008, 34:453-475

[414] Kurabayashi A et al. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma. Cancer Sci., 2015, 106:1092-1099

[415] Stopeck AT et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol., 2010, 28:5132-5139

[416] Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011, 377:813-822

[417] Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone, 2011, 48:96-99

[418] Schieferdecker A et al. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget, 2014, 5:6647-6653

[419] Liu Y et al. AB0078|Role of IL-8 and Its Receptor in Anti-Citrullinated Protein Antibody Mediated Osteoclastogenesis in RA. Ann. Rheum. Dis., 2016, 75:923

[420] Duda DG et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res., 2011, 17:2074-2080

[421] Batchelor TT et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007, 11:83-95

[422] Batchelor TT et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol., 2010, 28:2817-2823

[423] di Tomaso E et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res., 2011, 71:19-28

[424] Kamoun WS et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol., 2009, 27:2542-2552

[425] Hiratsuka S et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc. Natl Acad. Sci. USA, 2011, 108:302-307

[426] Shaked Y et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell, 2008, 14:263-273

[427] Shaked Y et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res., 2009, 69:7524-7528

[428] Kozin SV et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res., 2010, 70:5679-5685

[429] Kioi M et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Investig., 2010, 120:694-705

[430] Chang CC et al. Dose-dependent effect of radiation on angiogenic and angiostatic CXC chemokine expression in human endothelial cells. Cytokine, 2009, 48:295-302

[431] Padua D et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 2008, 133:66-77

[432] Tan AR, Alexe G, Reiss M. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res. Treat., 2009, 115:453-495

[433] Biswas S et al. Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS ONE, 2011, 6

[434] Ganapathy V et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer, 2010, 9

[435] Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J. Immunol., 1989, 142:1536-1541

[436] Andrade SE, Donahue JG, Chan KA, Watson DJ, Platt R. Liver function testing in patients on HMG-CoA reductase inhibitors. Pharmacoepidemiol. Drug Saf., 2003, 12:307-313

[437] Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 2002, 16:508-519

[438] Liu CM et al. In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression. PLoS ONE, 2013, 8

[439] Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG, Ghosh-Choudhury N. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J. Biol. Chem., 2011, 286:11314-11327

[440] Asanuma K et al. The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. Breast Cancer, 2013, 20:241-246

[441] Nelson JB et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J. Urol., 2003, 169:1143-1149

[442] Pu R et al. Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. Oncol. Lett., 2016, 12:2023-2027

[443] Mandal CC, Ghosh-Choudhury T, Yoneda T, Choudhury GG, Ghosh-Choudhury N. Fish oil prevents breast cancer cell metastasis to bone. Biochem. Biophys. Res. Commun., 2010, 402:602-607

[444] Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate, 2007, 67:790-797

[445] Isaacs JT et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate, 2006, 66:1768-1778

[446] Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin. Investig. Drugs, 2010, 19:1235-1243

[447] Bratt O et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br. J. Cancer, 2009, 101:1233-1240

[448] Jennbacken K et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate, 2012, 72:913-924

[449] Shukeir N et al. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Br. J. Pharmacol., 2015, 172:2769-2781

[450] Petrel C et al. Positive and negative allosteric modulators of the Ca²⁺-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J. Biol. Chem., 2004, 279:18990-18997

[451] Chang W et al. Complex formation with the Type B gamma-aminobutyric acid receptor affects the expression and signal transduction of the extracellular calcium-sensing receptor. Studies with HEK-293 cells and neurons. J. Biol. Chem., 2007, 282:25030-25040

[452] Kumar S et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone, 2010, 46:534-542

[453] Henry JG, Mitnick M, Dann PR, Stewart AF. Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. J. Clin. Endocrinol. Metab., 1997, 82:900-906

[454] Horwitz MJ et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J. Clin. Endocrinol. Metab., 2010, 95:1279-1287

[455] Mooberry SL. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr. Opin. Oncol., 2003, 15:425-430

[456] Mabjeesh NJ et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 2003, 3:363-375

[457] Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist. Updat., 2003, 6:355-361

[458] Tinley TL et al. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res., 2003, 63:1538-1549

[459] Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther., 2004, 3:647-654

[460] Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res., 2006, 4:601-605

Funding

This work is supported by the National Natural Science Foundation of China (No. 81602492), National Key Research and Development Program of China (No. 2016YFA0201402), and National Major Scientific and Technological Special Project for “Significant New Drugs Development” (No. 2018ZX09733001).